

COD 31011 50 tests	COD 31311 100 tests	COD 31012 150 tests	COD 31107 50 tests
STORE AT 2-8°C			
Reagents for determination of CRP Only for <i>in vitro</i> use in the clinical laboratory			

## C-REACTIVE PROTEIN (CRP) - SLIDE



BioSystems

C-REACTIVE PROTEIN (CRP)  
LATEX

### PRINCIPLE OF THE METHOD

Serum C-reactive protein (CRP) at 6 mg/L or higher causes a visible agglutination on slide of a suspension of latex particles coated with anti-human C-reactive protein<sup>1,2</sup>.

### CONTENTS

	COD 31011	COD 31311	COD 31012	COD 31107
A. Reagent	1 x 3 mL	2 x 3 mL	1 x 8 mL	1 x 3 mL
C-. Negative Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
C+. Positive Control	1 x 1 mL	1 x 1 mL	1 x 1 mL	-
Test Cards	3	6	6	-
Disposable stirrer sticks	1 x 50	1 x 150	1 x 150	-

### COMPOSITION

A. Reagent: Suspension of latex particles coated with anti-human C-reactive protein, sodium azide 0.95 g/L, borate buffer 100 mmol/L, pH 8.2.

C-. Negative Control: Serum containing CRP < 6 mg/L.

C+. Positive Control: Human serum containing CRP > 6 mg/L.

*Human sera used in the preparation of the positive and negative controls have been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the controls should be handled cautiously as potentially infectious.*

Test Cards.(Note 1)

Disposable stirrer sticks.

### STORAGE

Store at 2-8°C. Cards and stirrer sticks may be kept at room temperature.

Reagent and Controls are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.

Indications of deterioration:

– Reagent: Visible agglutination in the flask.

– Controls: Presence of particulate material.

### REAGENT PREPARATION

Reagent and controls are provided ready to use.

### ADDITIONAL EQUIPMENT

– Mechanical rotator adjustable to 100 r.p.m.

– For code 31107 test cards and stirrer sticks will be required.

### SAMPLES

Serum collected by standard procedures.

CRP in serum is stable for 7 days at 2-8°C.

### PROCEDURE

1. Bring test reagents and samples to room temperature (Note 2).
2. Place 50 µL of the sample and 1 drop of each Control into separate circles on the test card.
3. Shake the latex vial (A) gently repeatedly until complete resuspension of the latex particles. Hold the Reagent vial (A) in vertical position and add 1 drop of Reagent (A) to each circle next to the sample to be tested (Note 3).
4. Mix with a disposable stirrer stick and spread over the entire area enclosed by the ring. Use a new stirrer stick for each sample.
5. Rotate cards at 100 r.p.m. for 2 minutes.

### READING

Examine the presence of visible agglutination within a minute after removing the card from the rotator (Note 4).

Positive results: The presence of a visible agglutination indicates an PCR concentration in the sample  $\geq$  6 mg/L. Positive sera may be titrated. To titrate make serial two-fold dilutions in 9 g/L NaCl. The serum titer is defined as the highest dilution showing a positive result. The approximate PCR concentration in the sample may be obtained by multiplying the titer by 6 mg/L.

Negative results: The absence of a visible agglutination indicates a content of CRP < 6 mg/L.

### QUALITY CONTROL

Positive (C+) and Negative (C-) Controls provided with kits should be tested together with the patients samples, in order to verify the assay performance.

Positive Control (C+) should cause a clear visible agglutination of the latex particles.

Negative Control (C-) should not cause any agglutination of the latex particles.

Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

### ASSAY CHARACTERISTICS

– Detectability: 6 mg/L CRP, using an internal standard traceable to the Standard Reference Material BCR 470 (Institute for Reference Materials and Measurements, IRMM). The cut off value may vary up to 25% depending on uncontrolled variations in the procedure and on the operator experience in reading.

– High dose (zone) effect: False negative results due to high dose effect are absent at least up to 250 mg/L.

– False results: Results obtained with this reagent did not show significant differences when compared with reference reagents. Details of the comparison experiments are available on request.

– Interferences: Hemoglobin (5 g/L), bilirubin (15 mg/dL) and lipemia (5 g/L) do not interfere. Rheumatoid factors may interfere (25 IU/mL). Other drugs and substances may interfere<sup>3</sup>.

### DIAGNOSTIC CHARACTERISTICS

C-Reactive Protein (CRP), which is synthesized in the liver, is one of the most sensitive acute phase reactants after tissue damage or inflammation. CRP activates the classical complement pathway as a response to the inflammatory reaction.

CRP levels in plasma can rise dramatically after myocardial infarction, stress, trauma, infection, inflammation, surgery or neoplastic proliferation. The increase occurs within 24 to 48 hours and the level may be 2000 times normal. An elevation can be expected in virtually all diseases involving tissue damages so the finding is nonspecific<sup>4,5</sup>.

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

### NOTES

1. The test cards are reusable, and must be washed out and thoroughly rinsed with distilled water free of all detergents.
2. The sensitivity of the test may be reduced at low temperatures.
3. The presence of agglutinated particles at this point may be due to a lack of homogenization of the reagent.
4. Delay in reading may cause false positive results.

### BIBLIOGRAPHY

1. Singer JM, Plotz CM, Pader E, Elster SK. The latex-fixation test. III. Agglutination test for c-reactive protein and comparison with the capillary precipitin method. *Am J Clin Pathol* 1957; 28:611.
2. Hokama Y, Nakamura RM. C-reactive protein: current status and future perspectives. *J Clin Anal* 1987; 1: 15-27.
3. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.
4. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.
5. Immunology and Serology in Laboratory Medicine, 2<sup>nd</sup> edition. Turgeon ML. Mosby, 1996.

